Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03605238
Recruitment Status : Withdrawn (It was hard to recruit patients)
First Posted : July 30, 2018
Last Update Posted : September 19, 2019
Information provided by (Responsible Party):
Wei Shihui, Chinese PLA General Hospital

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : August 15, 2019
Estimated Study Completion Date : August 15, 2020